A. Tammaro, M. Derive, S. Gibot, J. C. Leemans, S. Florquin et al., TREM-1 and its potential ligands in non-infectious diseases: from biology to clinical perspectives, Pharmacology & Therapeutics. sept, vol.177, pp.81-95, 2017.

A. Boufenzer, J. Lemarie, T. Simon, M. Derive, Y. Bouazza et al., TREM-1 Mediates Inflammatory Injury and Cardiac Remodeling Following Myocardial Infarction. Circulation Research. 22 mai, vol.116, pp.1772-82, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01514439

J. Kuai, B. Gregory, A. Hill, D. D. Pittman, J. L. Feldman et al., TREM-1 expression is increased in the synovium of rheumatoid arthritis patients and induces the expression of proinflammatory cytokines, Rheumatology, vol.48, issue.11, pp.1352-1360, 2009.

Y. Murakami, T. Akahoshi, N. Aoki, M. Toyomoto, N. Miyasaka et al., Intervention of an inflammation amplifier, triggering receptor expressed on myeloid cells 1, for treatment of autoimmune arthritis, Arthritis & Rheumatism. juin, vol.60, issue.6, pp.1615-1638, 2009.

Y. Molad, S. Ofer-shiber, E. Pokroy-shapira, O. S. Shay-aharoni, H. Babai et al., Soluble triggering receptor expressed on myeloid cells-1 is a biomarker of anti-CCP-positive, early rheumatoid arthritis, European Journal of Clinical Investigation. juin, vol.45, issue.6, pp.557-64, 2015.

S. T. Choi, E. Kang, Y. J. Ha, and J. Song, Levels of Plasma-soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) Are Correlated with Disease Activity in Rheumatoid Arthritis, The Journal of Rheumatology. 1 mai, vol.39, issue.5, pp.933-941, 2012.

J. Gottenberg, O. Brocq, A. Perdriger, S. Lassoued, J. Berthelot et al., Non-TNFTargeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial, JAMA. 20 sept, vol.316, issue.11, pp.1172-80, 2016.

. Phd,

B. Fautrel, P. Md, and . Constantin,

G. Cormier, M. Salmon, M. Rist, and M. Lioté,

H. Marotte, P. Md, . Bonnet, . Md;-christian, M. D. Marcelli et al.,

E. Solau-gervais, M. D. Phd;-sandrine, M. D. Guis, P. Ziza, M. Zarnitsky et al.,

M. Pers, P. Md, M. Gayraud, . Bolla, M. D. Claudepierre et al.,

C. Balblanc, P. Md;-ouafaa-aberkane, P. Vazel, . Back, M. D. Phd;-sophie-candon et al., MD Fundings The main ROC study was sponsored by the French Ministry of Health (Programme Hospitalier de Recherche Clinique National 2009/4507 EUDRACT No: 2009-013482-26) and promoted by The Direction de la Recherche Clinique et de l'Innovation, Strasbourg University Hospital. The funding agency had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; the decision to submit for publication or preparation, review, or approval of the manuscript for publication

, Conflict of interest: none